The global clot busting drugs market is estimated to reach a market value of around USD 28.8 Billion in 2022, with the global market estimated to surge ahead at a CAGR value of 7.3% to reach a valuation of USD 58.4 Billion by the end of 2032. The injectable route of administration is driving the global clot busting drugs market as of 2021.
Market Outlook:
| Data | Market Insight |
|---|---|
| Estimated market Value 2022 | USD 28.8 Billion |
| Estimated market Value 2032 | USD 58.4 Billion |
| CAGR of 2022 to 2032 | 7.3 % |
| Market share of Top 5 countries | 57.4 % |
| Key Market players | Sanofi, Dr. Reddy’s Laboratories, Bayer AG, Boehringer Ingelheim Gmbh., Genentech Inc., Eli Lilly and Company, Johnson & Johnson Services Inc., The Medicines Company, Pfizer Inc. |
Abnormal blood clots are broken by clot-busting drugs. In the human body, a blood clot is a highly common and dangerous problem. A blood clot can obstruct veins and arteries, which can result in a hemorrhage, a stroke, or a heart attack. Clot-busting drugs work by breaking up aberrant blood clots and preserving regular blood flow.
Drugs that dissolve blood clots quickly help prevent many strokes. Clot-busting drugs can lessen the amount of brain damage that can result from a stroke by unblocking a clogged blood artery and restoring blood flow. Clot-busting medications must be administered within a few hours of the onset of stroke symptoms in order to be helpful.
The overall, clot busting drugs market sales account for approximately 17.3% of revenue share in the global cardiovascular drugs market, which was valued at around USD 155.6 Billion in 2021.
The global market for clot busting drugs recorded a historic CAGR of 7.3% in the last five years from 2016 to 2021.
The global market for clot busting drugs will be supported globally over the forecast period by the growing need for pharmaceuticals to treat heart attacks and strokes promptly. The development of clot busting therapeutic options and improvements in the pharmaceutical sector will further boost the growth of the global market for clot busting drugs.
Furthermore, as cardiovascular disorders like heart attacks and strokes become more common, the demand for clot busting drugs is anticipated to rise. The fifth most common cause of death in the USA is a stroke. The rising frequency of strokes needs an immediate response, and clot buster drugs can assist by dissolving the blood clot accumulating in the veins, which reduces blood pressure.
Strokes are increasing the rate of death in the population, which is causing the market for clot busting drugs to expand globally. Additionally, during the course of the forecast period, the increased risk of ischemic stroke in the global population is anticipated to boost the global market for clot busting drugs.
Additionally, stroke is the second leading cause of mortality worldwide, accounting for an estimated 5.5 million fatalities annually. Along with the enormous morbidity caused by stroke, which results in up to 50% of survivors having a long-term disability, there is also a significant mortality rate. As a result, stroke is a condition that is very important to public health and has major economic and social repercussions.
The global health impact of a stroke is expected to rise in the next years, especially in developing countries, which will boost the need for clot-busting drugs.
The cost of clot busting drugs that have shown to be particularly effective in treating ischemic stroke patients has more than doubled, considerably outpacing any Medicare/Medicaid reimbursements to hospitals that employ the medication.
Over the previous ten years, the price of alteplase (a clot busting drug) has climbed by 111%. According to Cardiovascular Business, the drug is particularly helpful in treating patients' acute ischemic stroke symptoms. If taken during the first few hours of a stroke, the medicine can frequently completely reverse its effects.
The global clot busting drugs market is thus likely to show high growth over the coming years a CAGR value of 7.3% and reach a global market size of USD 58.4 Billion by 2032.
During the projected period, there will be an increase in demand for pharmaceuticals to quickly treat heart attacks and strokes, which will lead to growth in the global market for clot-busting drugs. Developments in the pharmaceutical sector and the creation of clot-busting therapy options both influence the market's potential future expansion.
Tenecteplase, a newer generation clot busting medicine, outperforms the standard treatment for ischemic strokes in a number of critical areas, including improved health outcomes and lower costs, according to research that was conducted by the American Stroke Association.
The market for clot busting drugs will experience growth globally during the forecast period due to the increasing need for pharmaceutical products to promptly treat heart attacks and strokes.
For instance, non-fibrin-specific medications include plasminogen activating complex, streptokinase, and urokinase. Blood coagulation in the lungs is treated with urokinase, a drug of the serine protease class. Myocardial infarction, pulmonary embolism, and arterial thromboembolism are all conditions that are treated using the thrombolytic drug streptokinase.
The introduction of these innovative and better alternatives is expected to create a lucrative market for drug manufacturers and increase the adoption rate of their products, which will drive the Clot Busting drugs market in the projected period.
Drugs that target fibrin are fibrinolysis-inducing substances with negligible lytic effects, yet in stroke situations, they function as blood thinners. Tissue plasminogen activator (tPA), one of these medications, initiates the blood clots' disintegration when a stroked state is present.
The medication is exceedingly risky and should only be used under medical supervision due to the potential side effects of brain damage, paralysis, or even impaired speech. The tPA raises the likelihood of bleeding, it may not be possible for patients with a history of bleeding problems, recent operations, unstable blood pressure, or a recent severe concussion to get it.
A safe dose of the drug, which is administered intravenously, frequently does not remain in the bloodstream long enough to dissolve the large clots, and increasing the dose increases the risk of bleeding even though it is effective against smaller clots in thinner capillaries.
Additional adverse effects of these clot busting medications include bleeding from wounds or the area where the drug was shot, an allergic response, fever, reduced blood pressure, and signs of bleeding from other parts of the body, such as nosebleeds, black tarry stools, blood in the urine, and gum bleeding.
The aforementioned factors can serve as potential barriers to the expansion of the clot busting drugs market in the future.
The USA has dominated the North American region by reaching a worth of USD 8.4 Billion while withholding the vast majority of the worldwide market share of roughly 31.1% in 2021.
Nearly 8 lac strokes occur each year in the USA blood clot that blocks a vein supplying blood to the brain causes more than 85% of these strokes to be ischemic. The USA is anticipated to grow during the projected period for the same reason.
As of 2021, Germany has led the European clot busting drugs market withholding about 7.6% of the global market share. In Germany, between 30 to 40% of adults have excessive blood pressure. With age, the percentage rises. Every second individual is impacted starting around age 60. It may result in deadly outcomes such as cardiac arrhythmias, renal failure, a stroke, or a heart attack.
With a growing number of drug manufacturers for the conditions like stroke and an increasing pipeline of clot busting drugs, Germany clot busting drugs market is expected to show substantial growth over the projected period.
China accounted for USD 1.6 Billion withholding the majority of the East Asian market share as of 2021. With an aging population, China has made significant progress in reforming its healthcare system. It currently offers a basic kind of universal health insurance and generously subsidizes an expanding list of essential medications.
In an effort to make medicines, including certain products from Pfizer, GlaxoSmithKline, and Novartis, more affordable, China is expected to reduce the prices of roughly 400 drugs for respiratory disorders, fever, cardiovascular diseases, and pain by up to 20%. This is expected to boost the market for clot busting drugs in the future too within this region.
By product, anticoagulants have driven the global market by achieving a valuation of about USD 9.9 Billion in 2021 withholding the majority of the global market share of about 36.7%. Due to the rise in chronic diseases, the development of anticoagulant medicines has become more molecularly and biologically advanced. Emerging nations are increasingly using novel oral anticoagulants (NOACs) and over the forecast period, increasing product launches and approvals are anticipated to support market expansion.
For instance, Natco Pharma introduced a rivaroxaban molecule under the trade name RPIGAT in December 2020. This anticoagulant drug is used to treat and prevent blood clots.
By indication, pulmonary embolism has led the global market by achieving a valuation of USD 8.4 Billion by the end of 2021. The demand for clot busting drugs is expected to increase because those who are receiving chemotherapy or who have a family history of pulmonary embolism are most at risk. The market is expected to thrive as the number of cancer patients increases.
In 2020, cancer was responsible for around 10 million deaths, according to the World Health Organization. Additionally, it is projected that rising government investments to enhance public healthcare systems will accelerate market expansion.
The injectable dominated the market in terms of route of administration and is predicted to continue expanding, accounting for more than half of the global market. The primary factors driving the growth of this market are the increasing use of biological drugs, the number of chronic diseases, the surge in sharps injuries, and the benefits of injectables. These problems have raised the demand for devices like safety syringes, prefilled syringes, and auto-injectors.
By distribution channel, hospital pharmacies have led the global market by generating nearly one-third of the global revenue as of 2021. The growing incidence of chronic diseases, patient compliance, and the wide & easy availability of a variety of products within the hospital premises are all responsible for the high percentage of this segment.
Tissue plasminogen activator (tPA) and thrombolytic drugs have changed how heart attack patients are treated, and they have sparked competition among pharmaceutical companies.
In order to introduce new technologies and therapies, major companies in the global market for clot busting drugs are investing in research and development operations. To acquire a competitive edge, several of the other companies want to get product approvals for their new items. For example,
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2032 |
| Historical Data Available for | 2016 to 2021 |
| Market Analysis | USD Billion for Value |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; and Middle East & Africa (MEA). |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Rest of Latin America, United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, Nordic Countries, Rest of Europe, Japan, China, South Korea, India, Thailand, Indonesia, Malaysia, Vietnam, Philippines, Australia, New Zealand, Turkey, GCC, South Africa, Israel, North Africa and Rest of MEA. |
| Key Market Segments Covered | Product, Indication, Route of Administration Distribution Channel and Regions. |
| Key Companies Profiled | Sanofi; Dr. Reddy’s Laboratories; Bayer AG; Boehringer Ingelheim Gmbh.; Genentech Inc.; Eli Lilly and Company; Johnson & Johnson Services Inc.; The Medicines Company; Pfizer Inc. |
| Pricing | Available upon Request |
Table 01: Global Market Analysis 2016 to 2021 and Forecast 2022 to 2032, by Product
Table 02: Global Market Analysis 2016 to 2021 and Forecast 2022 to 2032, by Indication
Table 03: Global Market Analysis 2016 to 2021 and Forecast 2022 to 2032, by Route of Administration
Table 04: Global Market Analysis 2016 to 2021 and Forecast 2022 to 2032, by Distribution Channel
Table 05: Global Market Analysis 2016 to 2021 and Forecast 2022 to 2032, by Region
Table 06: North America Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast 2022 to 2032, by Country
Table 07: North America Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast 2022 to 2032, by Product
Table 08: North America Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast 2022 to 2032, by Indication
Table 09: North America Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast 2022 to 2032, by Route of Administration
Table 10: North America Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast 2022 to 2032, by Distribution Channel
Table 11: Latin America Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast 2022 to 2032, by Country
Table 12: Latin America Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast 2022 to 2032, by Product
Table 13: Latin America Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast 2022 to 2032, by Indication
Table 14: Latin America Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast 2022 to 2032, by Route of Administration
Table 15: Latin America Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast 2022 to 2032, by Distribution Channel
Table 16: Europe Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast 2022 to 2032, by Country
Table 17: Europe Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast 2022 to 2032, by Product
Table 18: Europe Market Analysis 2016 to 2021 and Forecast 2022 to 2032, by Indication
Table 19: Europe Market Analysis 2016 to 2021 and Forecast 2022 to 2032, by Route of Administration
Table 20: Europe Market Analysis 2016 to 2021 and Forecast 2022 to 2032, by Distribution Channel
Table 21: East Asia Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast 2022 to 2032, by Country
Table 22: East Asia Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast 2022 to 2032, by Product
Table 23: East Asia Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast 2022 to 2032, by Indication
Table 24: East Asia Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast 2022 to 2032, by Route of Administration
Table 25: East Asia Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast 2022 to 2032, by Distribution Channel
Table 26: South Asia Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast 2022 to 2032, by Country
Table 27: South Asia Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast 2022 to 2032, by Product
Table 28: South Asia Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast 2022 to 2032, by Indication
Table 29: South Asia Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast 2022 to 2032, by Route of Administration
Table 30: South Asia Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast 2022 to 2032, by Distribution Channel
Table 31: Oceania Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast 2022 to 2032, by Country
Table 32: Oceania Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast 2022 to 2032, by Product
Table 33: Oceania Market Analysis 2016 to 2021 and Forecast 2022 to 2032, by Indication
Table 34: Oceania Market Analysis 2016 to 2021 and Forecast 2022 to 2032, by Route of Administration
Table 35: Oceania Market Analysis 2016 to 2021 and Forecast 2022 to 2032, by Distribution Channel
Table 36: Middle East & Africa Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast 2022 to 2032, by Country
Table 37: Middle East & Africa Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast 2022 to 2032, by Product
Table 38: Middle East & Africa Market Analysis 2016 to 2021 and Forecast 2022 to 2032, by Indication
Table 39: Middle East & Africa Market Analysis 2016 to 2021 and Forecast 2022 to 2032, by Route of Administration
Table 40: Middle East & Africa Market Analysis 2016 to 2021 and Forecast 2022 to 2032, by Distribution Channel
Figure 01: Global Market Value (US$ Billion) Analysis, 2016 to 2021
Figure 02: Global Market Forecast & Y-o-Y Growth, 2022 to 2032
Figure 03: Global Market Absolute $ Opportunity (US$ Billion) Analysis, 2021 to 2032
Figure 04: Global Market Value Share (%) Analysis 2022 and 2032, by Product
Figure 05: Global Market Y-o-Y Growth (%) Analysis 2021 to 2032, by Product
Figure 06: Global Market Attractiveness Analysis 2022 to 2032, by Product
Figure 07: Global Market Value Share (%) Analysis 2022 and 2032, by Indication
Figure 08: Global Market Y-o-Y Growth (%) Analysis 2021 to 2032, by Indication
Figure 09: Global Market Attractiveness Analysis 2022 to 2032, by Indication
Figure 10: Global Market Value Share (%) Analysis 2022 and 2032, by Route of Administration
Figure 11: Global Market Y-o-Y Growth (%) Analysis 2021 to 2032, by Route of Administration
Figure 12: Global Market Attractiveness Analysis 2022 to 2032, by Route of Administration
Figure 13: Global Market Value Share (%) Analysis 2022 and 2032, by Distribution Channel
Figure 14: Global Market Y-o-Y Growth (%) Analysis 2021 to 2032, by Distribution Channel
Figure 15: Global Market Attractiveness Analysis 2022 to 2032, by Distribution Channel
Figure 16: Global Market Value Share (%) Analysis 2022 and 2032, by Region
Figure 17: Global Market Y-o-Y Growth (%) Analysis 2021 to 2032, by Region
Figure 18: Global Market Attractiveness Analysis 2022 to 2032, by Region
Figure 19: North America Market Value (US$ Billion) Analysis, 2016 to 2021
Figure 20: North America Market Value (US$ Billion) Forecast, 2022 to 2032
Figure 21: North America Market Value Share, by Product (2022 E)
Figure 22: North America Market Value Share, by Indication (2022 E)
Figure 23: North America Market Value Share, by Route of Administration (2022 E)
Figure 24: North America Market Value Share, by Distribution Channel (2022 E)
Figure 25: North America Market Value Share, by Country (2022 E)
Figure 26: North America Market Attractiveness Analysis by Product, 2022 to 2032
Figure 27: North America Market Attractiveness Analysis by Indication, 2022 to 2032
Figure 28: North America Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 29: North America Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 30: North America Market Attractiveness Analysis by Country, 2022 to 2032
Figure 31: U.S. Market Value Proportion Analysis, 2021
Figure 32: Global Vs. U.S. Growth Comparison
Figure 33: U.S. Market Share Analysis (%) by Product, 2021 & 2032
Figure 34: U.S. Market Share Analysis (%) by Indication, 2021 & 2032
Figure 35: U.S. Market Share Analysis (%) by Route of Administration, 2021 & 2032
Figure 36: U.S. Market Share Analysis (%) by Distribution Channel, 2021 & 2032
Figure 37: Canada Market Value Proportion Analysis, 2021
Figure 38: Global Vs. Canada. Growth Comparison
Figure 39: Canada Market Share Analysis (%) by Product, 2021 & 2032
Figure 40: Canada Market Share Analysis (%) by Indication, 2021 & 2032
Figure 41: Canada Market Share Analysis (%) by Route of Administration, 2021 & 2032
Figure 42: Canada Market Share Analysis (%) by Distribution Channel, 2021 & 2032
Figure 43: Latin America Market Value (US$ Billion) Analysis, 2016 to 2021
Figure 44: Latin America Market Value (US$ Billion) Forecast, 2022 to 2032
Figure 45: Latin America Market Value Share, by Product (2022 E)
Figure 46: Latin America Market Value Share, by Indication (2022 E)
Figure 47: Latin America Market Value Share, by Route of Administration (2022 E)
Figure 48: Latin America Market Value Share, by Distribution Channel (2022 E)
Figure 49: Latin America Market Value Share, by Country (2022 E)
Figure 50: Latin America Market Attractiveness Analysis by Product, 2022 to 2032
Figure 51: Latin America Market Attractiveness Analysis by Indication, 2022 to 2032
Figure 52: Latin America Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 53: Latin America Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 54: Latin America Market Attractiveness Analysis by Country, 2022 to 2032
Figure 55: Mexico Market Value Proportion Analysis, 2021
Figure 56: Global Vs Mexico Growth Comparison
Figure 57: Mexico Market Share Analysis (%) by Product, 2021 & 2032
Figure 58: Mexico Market Share Analysis (%) by Indication, 2021 & 2032
Figure 59: Mexico Market Share Analysis (%) by Route of Administration, 2021 & 2032
Figure 60: Mexico Market Share Analysis (%) by Distribution Channel, 2021 & 2032
Figure 61: Brazil Market Value Proportion Analysis, 2021
Figure 62: Global Vs. Brazil. Growth Comparison
Figure 63: Brazil Market Share Analysis (%) by Product, 2021 & 2032
Figure 64: Brazil Market Share Analysis (%) by Indication, 2021 & 2032
Figure 65: Brazil Market Share Analysis (%) by Route of Administration, 2021 & 2032
Figure 66: Brazil Market Share Analysis (%) by Distribution Channel, 2021 & 2032
Figure 67: Argentina Market Value Proportion Analysis, 2021
Figure 68: Global Vs Argentina Growth Comparison
Figure 69: Argentina Market Share Analysis (%) by Product, 2021 & 2032
Figure 70: Argentina Market Share Analysis (%) by Indication, 2021 & 2032
Figure 71: Argentina Market Share Analysis (%) by Route of Administration, 2021 & 2032
Figure 72: Argentina Market Share Analysis (%) by Distribution Channel, 2021 & 2032
Figure 73: Europe Market Value (US$ Billion) Analysis, 2016 to 2021
Figure 74: Europe Market Value (US$ Billion) Forecast, 2022 to 2032
Figure 75: Europe Market Value Share, by Product (2022 E)
Figure 76: Europe Market Value Share, by Indication (2022 E)
Figure 77: Europe Market Value Share, by Route of Administration (2022 E)
Figure 78: Europe Market Value Share, by Distribution Channel (2022 E)
Figure 79: Europe Market Value Share, by Country (2022 E)
Figure 80: Europe Market Attractiveness Analysis by Product, 2022 to 2032
Figure 81: Europe Market Attractiveness Analysis by Indication, 2022 to 2032
Figure 82: Europe Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 83: Europe Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 84: Europe Market Attractiveness Analysis by Country, 2022 to 2032
Figure 85: UK Market Value Proportion Analysis, 2021
Figure 86: Global Vs. UK Growth Comparison
Figure 87: UK Market Share Analysis (%) by Product, 2021 & 2032
Figure 88: UK Market Share Analysis (%) by Indication, 2021 & 2032
Figure 89: UK Market Share Analysis (%) by Route of Administration, 2021 & 2032
Figure 90: UK Market Share Analysis (%) by Distribution Channel, 2021 & 2032
Figure 91: Germany Market Value Proportion Analysis, 2021
Figure 92: Global Vs. Germany Growth Comparison
Figure 93: Germany Market Share Analysis (%) by Product, 2021 & 2032
Figure 94: Germany Market Share Analysis (%) by Indication, 2021 & 2032
Figure 95: Germany Market Share Analysis (%) by Route of Administration, 2021 & 2032
Figure 96: Germany Market Share Analysis (%) by Distribution Channel, 2021 & 2032
Figure 97: Italy Market Value Proportion Analysis, 2021
Figure 98: Global Vs. Italy Growth Comparison
Figure 99: Italy Market Share Analysis (%) by Product, 2021 & 2032
Figure 100: Italy Market Share Analysis (%) by Indication, 2021 & 2032
Figure 101: Italy Market Share Analysis (%) by Route of Administration, 2021 & 2032
Figure 102: Italy Market Share Analysis (%) by Distribution Channel, 2021 & 2032
Figure 103: France Market Value Proportion Analysis, 2021
Figure 104: Global Vs France Growth Comparison
Figure 105: France Market Share Analysis (%) by Product, 2021 & 2032
Figure 106: France Market Share Analysis (%) by Indication, 2021 & 2032
Figure 107: France Market Share Analysis (%) by Route of Administration, 2021 & 2032
Figure 108: France Market Share Analysis (%) by Distribution Channel, 2021 & 2032
Figure 109: Spain Market Value Proportion Analysis, 2021
Figure 110: Global Vs Spain Growth Comparison
Figure 111: Spain Market Share Analysis (%) by Product, 2021 & 2032
Figure 112: Spain Market Share Analysis (%) by Indication, 2021 & 2032
Figure 113: Spain Market Share Analysis (%) by Route of Administration, 2021 & 2032
Figure 114: Spain Market Share Analysis (%) by Distribution Channel, 2021 & 2032
Figure 115: Russia Market Value Proportion Analysis, 2021
Figure 116: Global Vs Russia Growth Comparison
Figure 117: Russia Market Share Analysis (%) by Product, 2021 & 2032
Figure 118: Russia Market Share Analysis (%) by Indication, 2021 & 2032
Figure 119: Russia Market Share Analysis (%) by Route of Administration, 2021 & 2032
Figure 120: Russia Market Share Analysis (%) by Distribution Channel, 2021 & 2032
Figure 121: BENELUX Market Value Proportion Analysis, 2021
Figure 122: Global Vs BENELUX Growth Comparison
Figure 123: BENELUX Market Share Analysis (%) by Product, 2021 & 2032
Figure 124: BENELUX Market Share Analysis (%) by Indication, 2021 & 2032
Figure 125: BENELUX Market Share Analysis (%) by Route of Administration, 2021 & 2032
Figure 126: BENELUX Market Share Analysis (%) by Distribution Channel, 2021 & 2032
Figure 127: East Asia Market Value (US$ Billion) Analysis, 2016 to 2021
Figure 128: East Asia Market Value (US$ Billion) Forecast, 2022 to 2032
Figure 129: East Asia Market Value Share, by Product (2022 E)
Figure 130: East Asia Market Value Share, by Indication (2022 E)
Figure 131: East Asia Market Value Share, by Route of Administration (2022 E)
Figure 132: East Asia Market Value Share, by Distribution Channel (2022 E)
Figure 133: East Asia Market Value Share, by Country (2022 E)
Figure 134: East Asia Market Attractiveness Analysis by Product, 2022 to 2032
Figure 135: East Asia Market Attractiveness Analysis by Indication, 2022 to 2032
Figure 136: East Asia Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 137: East Asia Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 138: East Asia Market Attractiveness Analysis by Country, 2022 to 2032
Figure 139: China Market Value Proportion Analysis, 2021
Figure 140: Global Vs. China Growth Comparison
Figure 141: China Market Share Analysis (%) by Product, 2021 & 2032
Figure 142: China Market Share Analysis (%) by Indication, 2021 & 2032
Figure 143: China Market Share Analysis (%) by Route of Administration, 2021 & 2032
Figure 144: China Market Share Analysis (%) by Distribution Channel, 2021 & 2032
Figure 145: Japan Market Value Proportion Analysis, 2021
Figure 146: Global Vs. Japan Growth Comparison
Figure 147: Japan Market Share Analysis (%) by Product, 2021 & 2032
Figure 148: Japan Market Share Analysis (%) by Indication, 2021 & 2032
Figure 149: Japan Market Share Analysis (%) by Route of Administration, 2021 & 2032
Figure 150: Japan Market Share Analysis (%) by Distribution Channel, 2021 & 2032
Figure 151: South Korea Market Value Proportion Analysis, 2021
Figure 152: Global Vs South Korea Growth Comparison
Figure 153: South Korea Market Share Analysis (%) by Product, 2021 & 2032
Figure 154: South Korea Market Share Analysis (%) by Indication, 2021 & 2032
Figure 155: South Korea Market Share Analysis (%) by Route of Administration, 2021 & 2032
Figure 156: South Korea Market Share Analysis (%) by Distribution Channel, 2021 & 2032
Figure 157: South Asia Market Value (US$ Billion) Analysis, 2016 to 2021
Figure 158: South Asia Market Value (US$ Billion) Forecast, 2022 to 2032
Figure 159: South Asia Market Value Share, by Product (2022 E)
Figure 160: South Asia Market Value Share, by Indication (2022 E)
Figure 161: South Asia Market Value Share, by Route of Administration (2022 E)
Figure 162: South Asia Market Value Share, by Distribution Channel (2022 E)
Figure 163: South Asia Market Value Share, by Country (2022 E)
Figure 164: South Asia Market Attractiveness Analysis by Product, 2022 to 2032
Figure 165: South Asia Market Attractiveness Analysis by Indication, 2022 to 2032
Figure 166: South Asia Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 167: South Asia Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 168: South Asia Market Attractiveness Analysis by Country, 2022 to 2032
Figure 169: India Market Value Proportion Analysis, 2021
Figure 170: Global Vs. India Growth Comparison
Figure 171: India Market Share Analysis (%) by Product, 2021 & 2032
Figure 172: India Market Share Analysis (%) by Indication, 2021 & 2032
Figure 173: India Market Share Analysis (%) by Route of Administration, 2021 & 2032
Figure 174: India Market Share Analysis (%) by Distribution Channel, 2021 & 2032
Figure 175: Indonesia Market Value Proportion Analysis, 2021
Figure 176: Global Vs. Indonesia Growth Comparison
Figure 177: Indonesia Market Share Analysis (%) by Product, 2021 & 2032
Figure 178: Indonesia Market Share Analysis (%) by Indication, 2021 & 2032
Figure 179: Indonesia Market Share Analysis (%) by Route of Administration, 2021 & 2032
Figure 180: Indonesia Market Share Analysis (%) by Distribution Channel, 2021 & 2032
Figure 181: Malaysia Market Value Proportion Analysis, 2021
Figure 182: Global Vs. Malaysia Growth Comparison
Figure 183: Malaysia Market Share Analysis (%) by Product, 2021 & 2032
Figure 184: Malaysia Market Share Analysis (%) by Indication, 2021 & 2032
Figure 185: Malaysia Market Share Analysis (%) by Route of Administration, 2021 & 2032
Figure 186: Malaysia Market Share Analysis (%) by Distribution Channel, 2021 & 2032
Figure 187: Thailand Market Value Proportion Analysis, 2021
Figure 188: Global Vs. Thailand Growth Comparison
Figure 189: Thailand Market Share Analysis (%) by Product, 2021 & 2032
Figure 190: Thailand Market Share Analysis (%) by Indication, 2021 & 2032
Figure 191: Thailand Market Share Analysis (%) by Route of Administration, 2021 & 2032
Figure 192: Thailand Market Share Analysis (%) by Distribution Channel, 2021 & 2032
Figure 193: Oceania Market Value (US$ Billion) Analysis, 2016 to 2021
Figure 194: Oceania Market Value (US$ Billion) Forecast, 2022 to 2032
Figure 195: Oceania Market Value Share, by Product (2022 E)
Figure 196: Oceania Market Value Share, by Indication (2022 E)
Figure 197: Oceania Market Value Share, by Route of Administration (2022 E)
Figure 198: Oceania Market Value Share, by Distribution Channel (2022 E)
Figure 199: Oceania Market Value Share, by Country (2022 E)
Figure 200: Oceania Market Attractiveness Analysis by Product, 2022 to 2032
Figure 201: Oceania Market Attractiveness Analysis by Indication, 2022 to 2032
Figure 202: Oceania Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 203: Oceania Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 204: Oceania Market Attractiveness Analysis by Country, 2022 to 2032
Figure 205: Australia Market Value Proportion Analysis, 2021
Figure 206: Global Vs. Australia Growth Comparison
Figure 207: Australia Market Share Analysis (%) by Product, 2021 & 2032
Figure 208: Australia Market Share Analysis (%) by Indication, 2021 & 2032
Figure 209: Australia Market Share Analysis (%) by Route of Administration, 2021 & 2032
Figure 210: Australia Market Share Analysis (%) by Distribution Channel, 2021 & 2032
Figure 211: New Zealand Market Value Proportion Analysis, 2021
Figure 212: Global Vs New Zealand Growth Comparison
Figure 213: New Zealand Market Share Analysis (%) by Product, 2021 & 2032
Figure 214: New Zealand Market Share Analysis (%) by Indication, 2021 & 2032
Figure 215: New Zealand Market Share Analysis (%) by Route of Administration, 2021 & 2032
Figure 216: New Zealand Market Share Analysis (%) by Distribution Channel, 2021 & 2032
Figure 217: Middle East & Africa Market Value (US$ Billion) Analysis, 2016 to 2021
Figure 218: Middle East & Africa Market Value (US$ Billion) Forecast, 2022 to 2032
Figure 219: Middle East & Africa Market Value Share, by Product (2022 E)
Figure 220: Middle East & Africa Market Value Share, by Indication (2022 E)
Figure 221: Middle East & Africa Market Value Share, by Route of Administration (2022 E)
Figure 222: Middle East & Africa Market Value Share, by Distribution Channel (2022 E)
Figure 223: Middle East & Africa Market Value Share, by Country (2022 E)
Figure 224: Middle East & Africa Market Attractiveness Analysis by Product, 2022 to 2032
Figure 225: Middle East & Africa Market Attractiveness Analysis by Indication, 2022 to 2032
Figure 226: Middle East & Africa Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 227: Middle East & Africa Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 228: Middle East & Africa Market Attractiveness Analysis by Country, 2022 to 2032
Figure 229: GCC Countries Market Value Proportion Analysis, 2021
Figure 230: Global Vs GCC Countries Growth Comparison
Figure 231: GCC Countries Market Share Analysis (%) by Product, 2021 & 2032
Figure 232: GCC Countries Market Share Analysis (%) by Indication, 2021 & 2032
Figure 233: GCC Countries Market Share Analysis (%) by Route of Administration, 2021 & 2032
Figure 234: GCC Countries Market Share Analysis (%) by Distribution Channel, 2021 & 2032
Figure 235: Turkey Market Value Proportion Analysis, 2021
Figure 236: Global Vs. Turkey Growth Comparison
Figure 237: Turkey Market Share Analysis (%) by Product, 2021 & 2032
Figure 238: Turkey Market Share Analysis (%) by Indication, 2021 & 2032
Figure 239: Turkey Market Share Analysis (%) by Route of Administration, 2021 & 2032
Figure 240: Turkey Market Share Analysis (%) by Distribution Channel, 2021 & 2032
Figure 241: South Africa Market Value Proportion Analysis, 2021
Figure 242: Global Vs. South Africa Growth Comparison
Figure 243: South Africa Market Share Analysis (%) by Product, 2021 & 2032
Figure 244: South Africa Market Share Analysis (%) by Indication, 2021 & 2032
Figure 245: South Africa Market Share Analysis (%) by Route of Administration, 2021 & 2032
Figure 246: South Africa Market Share Analysis (%) by Distribution Channel, 2021 & 2032
Figure 247: North Africa Market Value Proportion Analysis, 2021
Figure 248: Global Vs North Africa Growth Comparison
Figure 249: North Africa Market Share Analysis (%) by Product, 2021 & 2032
Figure 250: North Africa Market Share Analysis (%) by Indication, 2021 & 2032
Figure 251: North Africa Market Share Analysis (%) by Route of Administration, 2021 & 2032
Figure 252: North Africa Market Share Analysis (%) by Distribution Channel, 2021 & 2032
The global clot busting drugs market is estimated to be worth USD 26.9 Billion at end of 2021.
The clot busting drugs market is expected to reach USD 58.4 Billion by end of 2032 growing at a CAGR of 7.3%.
Molecular and biological developments in clot busting drugs, new product approvals and launches, and increasing sedentary lifestyles among people leading to an increase in the prevalence of cardiovascular diseases are some of the key factors that drive this market.
The North American region has the highest market share of about 32.4% by the end of 2021 in the global clot busting drugs market.
South Asia is estimated to grow with a CAGR rate of 6.0% in the forecast duration of the global clot busting drugs market.
The USA, China, Germany, Japan, and the United Kingdom are the top five countries, which are expected to drive demand in the clot busting drugs market.
Sanofi, Dr. Reddy’s Laboratories, Bayer AG, Boehringer Ingelheim Gmbh., Genentech Inc., Eli Lilly and Company, Johnson & Johnson Services Inc., The Medicines Company, Pfizer Inc. are some of the key players in the clot busting drug industry.
From 2016 to 2021, the market for clot busting drugs expanded at the rate of 7.3%.
China accounted for 6.1% of the market share at the end of 2021 in the global market.
The United Kingdom displayed a market share of around 7.6% in 2021 in the global clot busting drugs market
Explore Similar Insights
Clot Busting Drugs Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
